CytaCoat AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CytaCoat AB - overview
Established
2001
Location
Solna, -, Sweden
Primary Industry
Pharmaceuticals
About
Based in Sweden, and founded in 2001, CytaCoat AB operates as a healthcare technology firm that develops antibacterial coatings for the prevention of healthcare-associated infections (HAIs) in patients. The company was founded by Jacob Odeberg and Birgitta Agerberth. In 2020, SMA Investment invested in CytaCoat AB. As of 2023, the company’s CEO is Graeme Brookes.
CytaCoat offers and develops anti-microbial coating technology, which is a drug-free and metal-free technology that is applied to various medical devices, including urinary catheters, venous catheters, dressings, and ventilators, to prevent infections in patients. The company’s technology consists of biocompatible organic components that eliminate healthcare-associated infections (HAIs) in patients.
Current Investors
Segulah Medical Acceleration
Primary Industry
Pharmaceuticals
Sub Industries
Healthcare IT, Pharmaceutical Research & Development
Website
www.cytacoat.com
Verticals
HealthTech
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
CytaCoat AB - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | CytaCoat AB | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.